期刊
MODERN RHEUMATOLOGY
卷 24, 期 5, 页码 715-724出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/14397595.2013.864224
关键词
Certolizumab pegol; Methotrexate; Randomized controlled trial; Rheumatoid arthritis; Tumor necrosis factor-alpha inhibitor
类别
资金
- UCB Pharma
- Pfizer
- Abbott
- Santen Mitsubishi-Tanabe
- Eisai
- Abott
- Astellas
- BMS
- Chugai
- Daiichi-Sankyo
- Janssen
- Mitsubishi-Tanabe
- Nippon Shinyaku
- Otsuka
- Sanofi-Aventis
- Santen
- Takeda
- Teijin
- Kaken and Pfizer
- MSD
- Kyorin
- Shionogi
- Taisho
- Dainippon-Sumitomo
- Taiho
- Toyama Chemical
- Meiji Seika
- AbbVie
- Amgen
- AstraZeneca
- Centocor
- Daiichi
- Eli Lilly
- GSK
- Merck
- Novartis
- Novo-Nordisk
- Roche
- Schering-Plough
- Vertex
Objectives. This 24-week, multicenter, double-blind, randomized, placebo-controlled study (NCT00791999) compared efficacy and safety of certolizumab pegol (CZP) in combination with methotrexate (MTX) vs placebo plus MTX in Japanese rheumatoid arthritis (RA) patients with inadequate response to MTX. Methods. In total, 316 patients were randomized 1: 1: 1: 1 to subcutaneous CZP 100, 200, or 400 mg (induction dose: 200 mg or 400 mg CZP at Weeks 0, 2, and 4) plus MTX or placebo plus MTX every 2 weeks. Primary endpoint was ACR20 response at Week 12. Results. ACR20 response rates were 62.5%, 76.8%, 77.6%, and 28.6% at Week 12, and 61.1%, 73.2%, 71.8%, and 24.7% at Week 24 for CZP 100, 200, and 400 mg, and placebo groups, respectively, with statistical significance between each CZP group and placebo. Change in Total Sharp Score over 24 weeks was significantly smaller in CZP 200 and 400 mg groups vs placebo. Improvements in health-related quality of life (HRQoL) were observed in all three CZP groups vs placebo. Incidence of adverse events was similar between CZP groups. Conclusions. CZP plus MTX resulted in rapid, sustained reductions in RA signs and symptoms in Japanese patients with inadequate response to MTX, with signifi cant inhibition of radiographic progression and improved HRQoL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据